varespladib has been researched along with Acute Coronary Syndrome in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kastelein, JJP; Lincoff, AM; Mani, P; Menon, V; Nicholls, SJ; Nissen, SE; Puri, R; Schwartz, GG; Shao, M | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Corsini, A; Ferri, N | 1 |
| Elliott, M; Goulder, M; Hislop, C; Rosenson, RS; Stasiv, Y; Waters, D | 1 |
| Cantor, WJ; Džavík, V; Horlick, EM; Ing, D; Lan, J; Lavi, S; Miner, SE; Osten, MD; Overgaard, CB; Plante, S; Robbins, K; Thorpe, K; Yip, PM | 1 |
| Rosenson, RS | 1 |
1 review(s) available for varespladib and Acute Coronary Syndrome
| Article | Year |
|---|---|
[Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Acute Coronary Syndrome; Atherosclerosis; Benzaldehydes; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Humans; Indoles; Keto Acids; Lipoproteins; Oximes; Phospholipase A2 Inhibitors; Phospholipases A | 2014 |
5 trial(s) available for varespladib and Acute Coronary Syndrome
| Article | Year |
|---|---|
Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Australia; C-Reactive Protein; Death; Europe; Female; Humans; India; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; New Zealand; North America; Phospholipase A2 Inhibitors; Placebos; Risk Factors; Stroke; Treatment Outcome | 2019 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Topics: Acetates; Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Prospective Studies; Pyrroles; Reference Values; Treatment Outcome | 2010 |
The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angioplasty; Biomarkers; Enzyme Inhibitors; Female; Humans; Indoles; Keto Acids; Male; Middle Aged; Phospholipases A2, Secretory | 2010 |
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Topics: Acetates; Acute Coronary Syndrome; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles | 2011 |